<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Intern. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id><journal-id journal-id-type="publisher-id">JVIM</journal-id><journal-title-group><journal-title>Journal of Veterinary Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0891-6640</issn><issn pub-type="epub">1939-1676</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29197122</article-id><article-id pub-id-type="pmc">5787154</article-id><article-id pub-id-type="doi">10.1111/jvim.14842</article-id><article-id pub-id-type="publisher-id">JVIM14842</article-id><article-categories><subj-group subj-group-type="overline"><subject>Standard Article</subject></subj-group><subj-group subj-group-type="heading"><subject>SMALL ANIMAL</subject><subj-group subj-group-type="heading"><subject>Standard Articles</subject><subj-group subj-group-type="heading"><subject>Infectious Disease</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Efficacy of Minocycline in Naturally Occurring Nonacute <italic>Ehrlichia canis</italic> Infection in Dogs</article-title><alt-title alt-title-type="left-running-head">Jenkins et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jvim14842-cr-0001" contrib-type="author"><name><surname>Jenkins</surname><given-names>S.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9838-7909</contrib-id><xref ref-type="aff" rid="jvim14842-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14842-cr-0002" contrib-type="author" corresp="yes"><name><surname>Ketzis</surname><given-names>J.K.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6351-3140</contrib-id><address><email>jketzis@rossu.edu</email></address><xref ref-type="aff" rid="jvim14842-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14842-cr-0003" contrib-type="author"><name><surname>Dundas</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="jvim14842-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jvim14842-cr-0004" contrib-type="author"><name><surname>Scorpio</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="jvim14842-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jvim14842-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jvim14842-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">One Health Center for Zoonoses and Tropical Veterinary Medicine</named-content>
<institution>Ross University School of Veterinary Medicine</institution>
<named-content content-type="city">Basseterre</named-content>
<named-content content-type="country-part">St. Kitts</named-content>
<country>West Indies</country>
</aff><aff id="jvim14842-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Vaccine Research Center</named-content>
<institution>National Institutes of Health</institution>
<named-content content-type="city">Bethesda</named-content>
<country>Maryland</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Corresponding author: J.K. Ketzis, Ross University School of Veterinary Medicine, Post Office Box&#x000a0;334, Basseterre, St Kitts, West Indies; e&#x02010;mail: <email>jketzis@rossu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>32</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/jvim.2018.32.issue-1</issue-id><fpage>217</fpage><lpage>221</lpage><history><date date-type="received"><day>30</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>29</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 American College of Veterinary Internal Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">Copyright &#x000a9; 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JVIM-32-217.pdf"/><abstract id="jvim14842-abs-0001"><sec id="jvim14842-sec-0001"><title>Background</title><p>Minocycline has been used in the treatment of <italic>Ehrlichia canis</italic> infection in dogs as an alternative to doxycycline, the recommended treatment. However, efficacy of this alternative therapy is unknown.</p></sec><sec id="jvim14842-sec-0002"><title>Objective</title><p>To assess the efficacy of minocycline in the treatment of natural occurring <italic>E.&#x000a0;canis</italic> infection in dogs.</p></sec><sec id="jvim14842-sec-0003"><title>Animals</title><p>Ten privately owned dogs of mixed breed positive for <italic>E.&#x000a0;canis</italic> by blood <styled-content style="fixed-case">PCR</styled-content>.</p></sec><sec id="jvim14842-sec-0004"><title>Methods</title><p>Prospective, randomized clinical study. Dogs positive for <italic>E.&#x000a0;canis</italic> by <styled-content style="fixed-case">PCR</styled-content> were housed in a kennel environment and randomly allocated to receive doxycycline 10&#x000a0;mg/kg bodyweight <styled-content style="fixed-case">PO</styled-content> once daily (&#x0201c;gold standard&#x0201d; control group) or minocycline (extralabel) 10&#x000a0;mg/kg bodyweight <styled-content style="fixed-case">PO</styled-content> twice daily (treatment test group) for 28&#x000a0;days. Blood, analyzed by <styled-content style="fixed-case">PCR</styled-content> to determine the presence or absence of <italic>E.&#x000a0;canis</italic>
<styled-content style="fixed-case">DNA</styled-content>, was collected weekly during treatment starting on the first day of treatment and including through day 35, 7&#x000a0;days after the last treatment.</p></sec><sec id="jvim14842-sec-0005"><title>Results</title><p>In both groups, one dog tested negative after 7&#x000a0;days of treatment. For the doxycycline group, the latest time to a negative <styled-content style="fixed-case">PCR</styled-content> test was after 3&#x000a0;weeks of treatment. For the minocycline group, the latest time was on day 28 of treatment. All dogs tested negative 7&#x000a0;days after the end of treatment.</p></sec><sec id="jvim14842-sec-0006"><title>Conclusion and Clinical Importance</title><p>Minocycline can be an effective alternative to doxycycline for clearing <italic>E.&#x000a0;canis</italic> from the blood in nonacute infections.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvim14842-kwd-0001">Antibiotic</kwd><kwd id="jvim14842-kwd-0002"><italic>Ehrlichia</italic></kwd><kwd id="jvim14842-kwd-0003">Tetracycline</kwd><kwd id="jvim14842-kwd-0004">Ticks</kwd></kwd-group><funding-group><award-group><funding-source>Devry Education Group</funding-source></award-group><award-group><funding-source>Ross University School of Veterinary Medicine intramural grants</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="5"/><word-count count="4057"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jvim14842</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January/February 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.1.2 mode:remove_FC converted:28.01.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jvim14842-ntgp-0001"><fn id="jvim14842-note-1001"><p>This work was conducted on the island of St. Kitts utilizing the laboratory facilities at Ross University School of Veterinary Medicine and the kennels at Ponds Veterinary Clinic, Ponds Estate, Basseterre, St. Kitts.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="jvim14842-dl-0001"><title>Abbreviations</title><def-item><term>BW</term><def><p>body weight</p></def></def-item><def-item><term>CME</term><def><p>canine monocytic ehrlichiosis</p></def></def-item></def-list><p>Canine monocytic ehrlichiosis (CME), caused by <italic>Ehrlichia canis</italic>, is an endemic rickettsial disease present in much of the world.<xref rid="jvim14842-bib-0001" ref-type="ref">1</xref> The vector for <italic>E.&#x000a0;canis</italic> is <italic>Rhipicephalus sanguineus</italic>, the brown dog tick. In an experimental setting, after exposure to <italic>E.&#x000a0;canis</italic>, dogs enter an acute phase of disease (2&#x02013;4&#x000a0;weeks) followed by a subacute phase of infection. A chronic phase of infection, which manifests as a more complex inflammatory&#x000a0;disease, occurs in some dogs. Primary clinical signs of infection include lethargy, weight loss, and complications associated with thrombocytopenia. Death is a&#x000a0;potential outcome if effective treatment is not provided.<xref rid="jvim14842-bib-0002" ref-type="ref">2</xref>, <xref rid="jvim14842-bib-0003" ref-type="ref">3</xref> Detection of <italic>E.&#x000a0;canis</italic> infection can be challenging, with blood smears, serology, and PCR tests all having limitations regarding interpretation of results in relation to status of infection. Prevention is achieved with effective tick control; however, due to the intensity of <italic>R.&#x000a0;sanguineus</italic> populations in some geographical locations, transstadial transmission, and potential tick resistance to common acaricides, tick control can be challenging.<xref rid="jvim14842-bib-0004" ref-type="ref">4</xref>
</p><p>The recommended treatment for CME is doxycycline (10&#x000a0;mg/kg bodyweight [BW], PO once daily for 28&#x000a0;days), but other drugs such as amicarbalide, chloramphenicol, imidocarb dipropionate, and tetracycline have been studied.<xref rid="jvim14842-bib-0005" ref-type="ref">5</xref> While considered safe and effective, treatment failure at various dosages of doxycycline has been reported.<xref rid="jvim14842-bib-0005" ref-type="ref">5</xref>, <xref rid="jvim14842-bib-0006" ref-type="ref">6</xref>, <xref rid="jvim14842-bib-0007" ref-type="ref">7</xref>, <xref rid="jvim14842-bib-0008" ref-type="ref">8</xref> Some studies suggest that efficacy is related to the stage of infection, with chronic infections potentially more difficult to treat than acute or subacute.<xref rid="jvim14842-bib-0009" ref-type="ref">9</xref> Recent shortages of doxycycline suggest that identification of alternative treatments with similar properties to that of doxycycline would be beneficial.<xref rid="jvim14842-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim14842-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim14842-bib-0012" ref-type="ref">12</xref>
</p><p>Minocycline, another drug in the tetracycline family, has been used as an alternative to doxycycline in veterinary medical practices, with pharmacokinetic studies performed for some dieases.<xref rid="jvim14842-bib-0013" ref-type="ref">13</xref>, <xref rid="jvim14842-bib-0014" ref-type="ref">14</xref>, <xref rid="jvim14842-bib-0015" ref-type="ref">15</xref>, <xref rid="jvim14842-bib-0016" ref-type="ref">16</xref>, <xref rid="jvim14842-bib-0017" ref-type="ref">17</xref>, <xref rid="jvim14842-bib-0018" ref-type="ref">18</xref>, <xref rid="jvim14842-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim14842-bib-0020" ref-type="ref">20</xref> Little information is available regarding efficacy of minocycline for the treatment of rickettsial disease.<xref rid="jvim14842-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim14842-bib-0021" ref-type="ref">21</xref> The Centers for Disease Control and Prevention has not encouraged the treatment of human rickettsial infections with minocycline due to the lack of efficacy data.<xref rid="jvim14842-bib-0010" ref-type="ref">10</xref> In veterinary medicine, minocycline at 20&#x000a0;mg/kg PO Q12h has been suggested as a potentially effective treatment of CME.<xref rid="jvim14842-bib-0018" ref-type="ref">18</xref> The greater lipophilic properties and high tissue concentrations of minocycline could be beneficial in <italic>E.&#x000a0;canis</italic> treatment as compared to doxycycline.<xref rid="jvim14842-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim14842-bib-0020" ref-type="ref">20</xref> This may be especially true if <italic>E.&#x000a0;canis</italic> has invaded the central nervous system.<xref rid="jvim14842-bib-0022" ref-type="ref">22</xref>, <xref rid="jvim14842-bib-0023" ref-type="ref">23</xref>
</p><p>The objective of this study was to obtain preliminary data on the efficacy of minocycline in the treatment of dogs with naturally acquired CME as determined by peripheral blood clearance of DNA using PCR. The study was conducted on St. Kitts where there is only one species of <italic>Ehrlichia, E.&#x000a0;canis</italic>, and where CME is a commonly diagnosed disease.<xref rid="jvim14842-bib-0024" ref-type="ref">24</xref>
</p><sec id="jvim14842-sec-0008"><title>Materials and Methods</title><sec id="jvim14842-sec-0009"><title>Study Design, Animals, and Inclusion and Exclusion Criteria</title><p>This prospective, randomized, clinical study was conducted under the Ross University School of Veterinary Medicine Institutional Animal Care and Use Committee approved protocol 14&#x02010;7&#x02010;034. All animal housing facilities were inspected and approved by the committee. The efficacy of minocycline (extralabel) was tested with doxycycline used as a positive control (&#x0201c;gold standard&#x0201d;). Upon obtaining informed owner consent, male and female dogs of any breed were recruited for use in the study and subsequently returned to the owners after the study. Before enrollment, dogs were screened for <italic>E.&#x000a0;canis</italic> exposure by serology by a commercial antibody test.<xref ref-type="fn" rid="jvim14842-note-1002">a</xref> Samples positive for <italic>Ehrlichia</italic> spp. were further tested by PCR. Dogs positive by PCR and deemed healthy to participate, based on a physical examination, were included in the study.</p><p>Thirteen dogs were identified for inclusion and enrolled in the study. An acclimation period of 28&#x000a0;days was used to confirm infection status and to ensure dogs were beyond the acute infection period. PCR tests for <italic>E.&#x000a0;canis</italic> were performed during the acclimation period to verify continued infection. Also during this time, and throughout the study, dogs were treated for ticks to control infestation.<xref ref-type="fn" rid="jvim14842-note-1003">b</xref> The dogs also received pyrantel pamoate as a general dewormer.<xref ref-type="fn" rid="jvim14842-note-1004">c</xref>
</p><p>Allocation to treatment group occurred on the day of first treatment (N&#x000a0;=&#x000a0;6 per group; one of the 13 dogs died during acclimation due to an unrelated cause). Randomization was performed by generating a coin toss table, utilizing heads for minocycline and tails for doxycycline. Names of the dogs were drawn from a hat and assigned, sequentially, to the head/tail chart. Doxycycline<xref ref-type="fn" rid="jvim14842-note-1005">d</xref> was administered PO as per the recommended dose (10&#x000a0;mg/kg BW once daily); minocycline<xref ref-type="fn" rid="jvim14842-note-1006">e</xref> was administered PO twice daily at 10&#x000a0;mg/kg BW. Treatments were administered at feeding time using capsules of 50 or 100&#x000a0;mg. The first treatment occurred on day 1 with the final treatment on day 28 of the study. Treatments were administered at approximately the same time each day.</p></sec><sec id="jvim14842-sec-0010"><title>Schedule of Events</title><p>Thirteen dogs, presenting at the Ponds Veterinary Clinic between October and November 2014, were identified as positive for <italic>E.&#x000a0;canis</italic> by PCR. In December 2014, all identified dogs were housed in an approved outdoor kennel facility for an acclimation period (28&#x000a0;days). During acclimation and throughout the study, dogs remained under the primary care of the clinic with secondary veterinary care provided by the Ross University Veterinary Clinic.</p><p>A basic physical examination was performed before being placed on acclimation, and a comprehensive examination was performed before treatment. After acclimation, treatment started on day 1 and ended on day 28. Blood collection for PCR analysis occurred on days 1, 7, 14, 21, 28, and 35. Hematology analysis (22&#x02010;parameter CBC including PLT, PCV, WBC, LYM, NEU, and HGB) was performed on blood before treatment and on days 28 and 35.<xref ref-type="fn" rid="jvim14842-note-1007">f</xref> Clinical chemistry analysis (ALB, ALP, ALT, TBil, BUN, Ca, Phos, Cre, Glu, Na, K, TP, and Glob) was performed on blood collected pretreatment and on day 35.<xref ref-type="fn" rid="jvim14842-note-1008">g</xref> During acclimation and treatment, general health observations (alertness, fecal consistency, feed consumption, eyes [discharge or other abnormality], and respiration) were performed twice daily with any abnormalities noted. The dogs were monitored on days 1&#x02013;35 for any adverse events, suspected to be related or not related to treatment, and treated as appropriate. Dogs were returned to their owners at the completion of the study.</p></sec><sec id="jvim14842-sec-0011"><title>
<italic>Ehrlichia canis</italic> Detection</title><p>
<italic>Ehrlichia canis</italic> exposure was determined by an antibody test for <italic>E.&#x000a0;canis</italic> and <italic>Ehrlichia ewingii,</italic> and infection was confirmed by PCR using a previously published protocol for <italic>Ehrlichia</italic> species.<xref rid="jvim14842-bib-0025" ref-type="ref">25</xref>, <xref rid="jvim14842-bib-0026" ref-type="ref">26</xref>
<italic>Ehrlichia ewingii</italic> nor the vector, <italic>Amblyomma americanum,</italic> is not known to exist on St. Kitts and, therefore, positive results with both tests were used to confirm <italic>E.&#x000a0;canis</italic> infection.<xref rid="jvim14842-bib-0027" ref-type="ref">27</xref> For the PCR analysis, DNA was extracted from 100&#x000a0;&#x003bc;L of blood or buffy coat with a standard kit.<xref ref-type="fn" rid="jvim14842-note-1009">h</xref> Elution was performed with 200&#x02010;&#x003bc;L manufacturer's buffer or 50&#x000a0;&#x003bc;L, followed by 100&#x000a0;&#x003bc;L buffer. Presence of DNA in the samples was confirmed by NanoQuant absorbance.<xref ref-type="fn" rid="jvim14842-note-1010">i</xref> Positive and negative controls were included and consisted of DNA from a confirmed positive dog and the reagents with DNase&#x02010;free distilled water, respectively. PCR was performed by &#x0201c;Kiss&#x0201d; Fluorescence Resonance Energy Transfer (FRET) and a Roche LightCycler 2.0 for DNA amplification and software analysis.<xref ref-type="fn" rid="jvim14842-note-1011">j</xref> PCR analysis was performed, targeting the 16s rRNA (<italic>rrs</italic>) gene with the following primers: forward primer (5&#x02032;&#x02010;GAGGATTTTATCTTTGTATTGTAGCTAAC&#x02010;3&#x02032;), reverse primer (5&#x02032;&#x02010;TGTAAGGTCCAGCCGAACTGACT&#x02010;3&#x02032;), fluorescein probe (5&#x02032;&#x02010;ACGCGAAAAACCTTACCACTTTTTGAC&#x02010;6&#x02010;FAM&#x02010;3&#x02032;), and the LCRed 640 probe (5&#x02032;&#x02010;LCRed640&#x02010;X<sub>n</sub>&#x02010;phosphate&#x02010;3&#x02032;)g with a sensitivity of 5 copies per PCR.<xref ref-type="fn" rid="jvim14842-note-1012">k</xref> A positive amplification curve and the melting temperature were used to confirm the presence of <italic>E.&#x000a0;canis</italic> DNA.<xref rid="jvim14842-bib-0025" ref-type="ref">25</xref>
</p></sec><sec id="jvim14842-sec-0012"><title>Outcome Evaluation and Statistical Analysis</title><p>The primary outcome of this study was to assess the treatment success of minocycline with success defined as negative PCR results from peripheral blood. Statistical comparisons between groups (Mann&#x02013;Whitney test)<xref ref-type="fn" rid="jvim14842-note-1013">l</xref> were conducted to determine whether there was a difference in the time to clearance between antibiotics.</p></sec></sec><sec id="jvim14842-sec-0013"><title>Results</title><p>In this study, 2 dogs tested negative for <italic>E.&#x000a0;canis</italic> by PCR on day 1 and were therefore excluded from statistical analysis, resulting in five dogs (4 males and 1 female) per treatment group. In the minocycline group, dogs ranged from 1 to 6&#x000a0;years of age and 3 to 21&#x000a0;kg BW. In the doxycycline group, dogs ranged from 3 to 6&#x000a0;years of age and 6 to 32&#x000a0;kg BW. One dog in each group was <italic>Anaplasma</italic> spp. antibody positive based on the commercial kit. Treatment administration was successful for all dogs on all days with the average dose of doxycycline being 12&#x000a0;mg/kg BW and for minocycline being 11&#x000a0;mg/kg BW. There were no adverse events related to treatments administered during the study. In addition to the tick control and endo&#x02010;parasite treatments, 1 dog in the doxycycline group received cephalexin (10&#x000a0;mg/kg BW BID&#x000a0;&#x000d7;&#x000a0;14&#x000a0;d). None of the concomitant treatments administered have known efficacy against or interaction with <italic>E.&#x000a0;canis</italic>.</p><p>Treatment success, narrowly defined as negative for <italic>E.&#x000a0;canis</italic> in peripheral blood by PCR by end of 28&#x000a0;days of treatment, was 100% in both groups (Table&#x000a0;<xref rid="jvim14842-tbl-0001" ref-type="table-wrap">1</xref>). In the doxycycline group, the earliest time to a negative test was after 7&#x000a0;days of treatment and the longest after 21&#x000a0;days of treatment (mean 2; median 2&#x000a0;weeks). In the minocycline group, the earliest time to a negative test also was after 7&#x000a0;days of treatment and the longest after 28&#x000a0;days of treatment (mean 2.2; median 2&#x000a0;weeks). No significant difference was found in the time to a negative test (Mann&#x02013;Whitney test; <italic>P&#x000a0;</italic>&#x0003e;<italic>&#x000a0;</italic>0.1). All dogs remained negative for <italic>E.&#x000a0;canis</italic> in peripheral blood 7&#x000a0;days after the last treatment.</p><table-wrap id="jvim14842-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Time to <italic>Ehrlichia canis</italic> clearance from blood based on PCR after commencement of treatment on day 0</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Cumulative Number of Dogs Negative at Each Time Point</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Days After Treatment Commenced</th><th align="center" valign="top" rowspan="1" colspan="1">Doxycycline Treated (N&#x000a0;=&#x000a0;5)</th><th align="center" valign="top" rowspan="1" colspan="1">Minocycline Treated (N&#x000a0;=&#x000a0;5)</th></tr></thead><tbody><tr><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr></tbody></table><table-wrap-foot><fn id="jvim14842-note-0002"><p>Results were not statistically significantly different.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Hematology and clinical chemistry revealed across both treatment groups the presence of thrombocytopenia, lymphocytosis, anemia, and hyperglobulinemia, which are all common parameters affected by <italic>E.&#x000a0;canis</italic> infection. Table&#x000a0;<xref rid="jvim14842-tbl-0002" ref-type="table-wrap">2</xref> provides an overview of how the parameters changed by end of the 28&#x02010;day treatment period and their status 7&#x000a0;days after treatment was completed.</p><table-wrap id="jvim14842-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Median value (minimum; maximum) of selected blood parameters of dogs with <italic>Ehrlichia canis</italic> and number of dogs below (&#x02193;) or above (&#x02191;) the normal range</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Parameter (Normal Range)</th><th align="left" valign="top" rowspan="1" colspan="1">PCV (37.5&#x02013;55.0%)</th><th align="left" valign="top" rowspan="1" colspan="1">Lymphocytes (1&#x02013;4.8&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">Platelets (200&#x02013;500&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>)</th><th align="left" valign="top" rowspan="1" colspan="1">Globulin (2.3&#x02013;5.2&#x000a0;g/dL)</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Doxycycline treated (N&#x000a0;=&#x000a0;5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pretreatment</td><td align="left" rowspan="1" colspan="1">
40 (31; 44)<break/>
1 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
2.8 (0.9; 7.0)<break/>
1 &#x02193;; 1 &#x02191;
</td><td align="left" rowspan="1" colspan="1">
86 (55; 225)<break/>
4 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
7.1 (3.8; 7.8)<break/>
4 &#x02191;
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Day 28 of treatment</td><td align="left" rowspan="1" colspan="1">
40<xref ref-type="fn" rid="jvim14842-note-0004">b</xref> (38; 45)<break/>
&#x02013;
</td><td align="left" rowspan="1" colspan="1">
2.6 (1.2; 6.4)<break/>
1 &#x02191;
</td><td align="left" rowspan="1" colspan="1">
175 (71; 285)<break/>
4 &#x02193;
</td><td align="left" rowspan="1" colspan="1">Not determined</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">7&#x000a0;days post&#x02010;treatment</td><td align="left" rowspan="1" colspan="1">
44 (38; 45)<break/>
&#x02013;
</td><td align="left" rowspan="1" colspan="1">
2.8 (0.7; 4.4)<break/>
1 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
225<xref ref-type="fn" rid="jvim14842-note-0005">c</xref> (90; 268)<break/>
2 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
4.7 (2.5; 6)<break/>
1 &#x02191;
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% change<xref ref-type="fn" rid="jvim14842-note-0005">c</xref>
</td><td align="left" rowspan="1" colspan="1">0 (&#x02212;5; 42)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;38; 84)</td><td align="left" rowspan="1" colspan="1">27 (4.7; 362)</td><td align="left" rowspan="1" colspan="1">&#x02212;34.2 (&#x02212;15.5; &#x02212;39.7)</td></tr><tr><td align="left" colspan="5" rowspan="1">Minocycline treated (N&#x000a0;=&#x000a0;5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pretreatment</td><td align="left" rowspan="1" colspan="1">
34 (28; 52)<break/>
4 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
2.1 (1.1; 4.9)<break/>
1 &#x02191;
</td><td align="left" rowspan="1" colspan="1">
141 (104; 261)<break/>
4 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
5.8 (2.6; 6.1)<break/>
3 &#x02191;
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Day 28 of treatment</td><td align="left" rowspan="1" colspan="1">
40 (34; 53)<break/>
2 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
1.8 (0.2; 4.8)<break/>
1 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
298 (144; 337)<break/>
2 &#x02193;
</td><td align="left" rowspan="1" colspan="1">Not determined</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">7&#x000a0;days post&#x02010;treatment</td><td align="left" rowspan="1" colspan="1">
40 (30; 50)<break/>
1 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
2.0 (1.2; 3.1)<break/>
&#x02013;
</td><td align="left" rowspan="1" colspan="1">
279 (152; 323)<break/>
2 &#x02193;
</td><td align="left" rowspan="1" colspan="1">
3.7<xref ref-type="fn" rid="jvim14842-note-0004">b</xref> (2.4; 5.3)<break/>
1 &#x02191;
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">% change<xref ref-type="fn" rid="jvim14842-note-0003">a</xref>
</td><td align="left" rowspan="1" colspan="1">14.3 (&#x02212;4; 24)</td><td align="left" rowspan="1" colspan="1">12.3 (&#x02212;52; 36)</td><td align="left" rowspan="1" colspan="1">61.5 (6.9; 211)</td><td align="left" rowspan="1" colspan="1">&#x02212;21.2 <xref ref-type="fn" rid="jvim14842-note-0004">b</xref>(&#x02212;7.7; &#x02212;43.1)</td></tr></tbody></table><table-wrap-foot><fn id="jvim14842-note-0003"><label>a</label><p>Percent change pre&#x02010; to 7&#x000a0;days post&#x02010;treatment calculated for each dog and then averaged for the treatment group. A negative number indicates a decrease in the value.</p></fn><fn id="jvim14842-note-0004"><label>b</label><p>Data for one dog missing.</p></fn><fn id="jvim14842-note-0005"><label>c</label><p>Platelet reading was 1 for one dog; a follow&#x02010;up reading was 244. Due to the discrepancy, this dog is omitted from the analysis on this day.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jvim14842-sec-0014"><title>Discussion</title><p>This pilot study demonstrates that minocycline, at 10&#x000a0;mg/kg twice daily for 28&#x000a0;days, successfully cleared or suppressed <italic>E.&#x000a0;canis</italic> below the detectable limits of the PCR method used in dogs with nonacute natural infections. Whereas the follow&#x02010;up samples 7&#x000a0;days after treatment remained below detectable limits, conclusions regarding complete clearance of the infections were not feasible. Even with the sensitivity of PCR, bacteria numbers can be suppressed below the detection limit with the use of antibiotics. This can lead to less reliable conclusions regarding complete bacterial clearance. Four dogs in the doxycycline treated group and two in the minocycline group were still thrombocytopenic at the end of treatment, suggesting that suppression occurred with both treatments versus clearance. However, the positive percent change in platelets, as well as one of the doxycycline treated thrombocytopenic dogs having normal platelet counts 7&#x000a0;days after completion of treatment, might also suggest a slow recovery.</p><p>Splenic and bone marrow PCR testing may have enabled detection of noncirculating <italic>E.&#x000a0;canis</italic> to determine whether suppression or clearance occurred. An alternative would have been the use of immunosuppressive steroids to force recrudescence of infection for improved PCR detection. Due to the use of private dogs and limitations imposed by the IACUC and the dog owners, biopsies and use of steroids were not permitted. Further retesting of dogs once returned to their owners was not an option due to the exceptionally high tick pressure found on St Kitts. If follow&#x02010;up samples were collected after return of the dogs to their owners and found to be positive, reinfection could not be excluded.</p><p>Within the limits of the study, the effect of minocycline and doxycycline was not different, providing evidence that minocycline could be an alternative treatment for <italic>E.&#x000a0;canis</italic> infections when doxycycline cannot be used or is not available. As stage of infection might influence the efficacy of treatment, additional studies with experimental infections with known day of infection and a quantified infection dose may be necessary to validate true clearance.<xref rid="jvim14842-bib-0003" ref-type="ref">3</xref>
</p><p>In a clinical setting, twice daily administration of minocycline might result in owner compliance issues when compared to doxycycline.<xref rid="jvim14842-bib-0028" ref-type="ref">28</xref> However, studies have shown that there is variability with doxycycline therapy in both peripheral blood and tissue clearance, resulting in the potential for re&#x02010;emergence from tissues once treatment has ended.<xref rid="jvim14842-bib-0009" ref-type="ref">9</xref> If organisms are surviving treatment in tissues, minocycline might be more effective due to the higher concentrations in critical tissues.<xref rid="jvim14842-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim14842-bib-0020" ref-type="ref">20</xref> Although the &#x0201c;gold standard&#x0201d; dosage given once daily was followed for this study, twice daily dosing (as was required by the pharmacokinetics of minocycline) might have altered the efficacy of doxycycline, possibly changing our current results.</p><p>Whereas this study provides evidence that minocycline clears or suppresses PCR detection of <italic>E.&#x000a0;canis</italic>, the group size was small and there was no untreated control group. These limitations occurred due to the limited housing capacity of the animal facility. We had intended to include six dogs per group, which based on estimates of power calculations would have allowed further comparisons between the two treatments. Unfortunately, one dog from each group had to be excluded due to negative PCR tests after acclimation was started. The spontaneous clearance of <italic>E.&#x000a0;canis</italic> in the peripheral blood of the two excluded dogs is a phenomenon that has been previously reported.<xref rid="jvim14842-bib-0006" ref-type="ref">6</xref>, <xref rid="jvim14842-bib-0029" ref-type="ref">29</xref> The infection could have entered a chronic stage with <italic>E.&#x000a0;canis</italic> organisms residing in tissues. However, we are not able to specifically explain this observation further from our data and results.</p><p>In conclusion, this study provides evidence that minocycline can clear or suppress circulating <italic>E.&#x000a0;canis</italic> and might be an alternative treatment to the &#x0201c;gold standard&#x0201d; doxycycline. Minocycline, being a close relative to doxycycline, is a logical choice for not only <italic>E.&#x000a0;canis</italic> but also likely for other members of the Anaplasmataceae and family Rickettsiales. Doxycycline shortages have occurred in the human medical and veterinary field, driving elevated prices.<xref rid="jvim14842-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim14842-bib-0012" ref-type="ref">12</xref> Minocycline as an alternative is widely available and may be remarkably much less expensive. With other drug characteristics such as high lipophilicity, low protein binding, and improved penetrance into tissues such as the brain,<xref rid="jvim14842-bib-0019" ref-type="ref">19</xref> minocycline could be more suitable to doxycycline in treating these elusive bacteria. More clinical studies and experimental studies, however, are required to evaluate minocycline in treating severe disease caused by <italic>E.&#x000a0;canis</italic> infections and in assessing the impact on clearance.</p></sec></body><back><ack id="jvim14842-sec-0015"><title>Acknowledgments</title><p>The authors acknowledge Trellor Fraites and the Diagnostic Services team at Ross University School of Veterinary Medicine. We also acknowledge Dr. Burnell Nisbett and Kurtis Greenaway at Ponds Veterinary Clinic. We thank the Devry Education Group and Ross University School of Veterinary Medicine for funding this research. The work was supported by Ross University School of Veterinary Medicine intramural grants.</p><sec id="jvim14842-sec-0016" sec-type="COI-statement"><title>Conflict of Interest Declaration</title><p>Authors declare no conflict of interest.</p></sec><sec id="jvim14842-sec-0017"><title>Off&#x02010;label Antimicrobial Declaration</title><p>Minocycline was used extralabel.</p></sec></ack><fn-group id="jvim14842-ntgp-0004"><title>Footnotes</title><fn id="jvim14842-note-1002"><label>1</label><p>IDEXX SNAP<sup>&#x000ae;</sup> 4Dx<sup>&#x000ae;</sup> Plus Test (Westbrook, ME)</p></fn><fn id="jvim14842-note-1003"><label>2</label><p>Frontline<sup>&#x000ae;</sup> Tritak<sup>&#x000ae;</sup> (Merial, Duluth, GA), NexGard chewable (Merial, Duluth, GA), Seresto<sup>&#x000ae;</sup> collars (Bayer AG, Leverkusen, Germany) and biweekly Frontline Plus<sup>&#x000ae;</sup> topical (Merial, Duluth, GA)</p></fn><fn id="jvim14842-note-1004"><label>3</label><p>Strongid<sup>&#x000ae;</sup> (Zoeitis, Florham Park, NJ)</p></fn><fn id="jvim14842-note-1005"><label>4</label><p>Doxycycline Monohydrate capsules (PAR Pharmaceutical Companies Inc., Spring Valley, New York, NY)</p></fn><fn id="jvim14842-note-1006"><label>5</label><p>Minocycline HCl capsules (Ranbaxy Pharmaceuticals, Princeton, NJ)</p></fn><fn id="jvim14842-note-1007"><label>6</label><p>Abaxis Vet Scan HM5 (Abaxis, Union City, CA)</p></fn><fn id="jvim14842-note-1008"><label>7</label><p>Abaxis Vet Scan VS2 (Abaxis, Union City, CA)</p></fn><fn id="jvim14842-note-1009"><label>8</label><p>Qiagen<sup>&#x000ae;</sup> DNeasy<sup>&#x000ae;</sup> Blood and Tissue Spin&#x02010;Column kits (Rohm and Haas Company, Philadelphia)</p></fn><fn id="jvim14842-note-1010"><label>9</label><p>TECAN infinite M200 PRO NanoQuant (Tecan Group Ltd. M&#x000e4;nnedorf, Switzerland)</p></fn><fn id="jvim14842-note-1011"><label>10</label><p>Light Cycler 2.0 (Roche Molecular Systems, Inc., Pleasanton, CA)</p></fn><fn id="jvim14842-note-1012"><label>11</label><p>IDT (Integrated DNA Technologies, Inc. Coralville, Iowa)</p></fn><fn id="jvim14842-note-1013"><label>12</label><p>VassarStats: Website for Statistical Computation. <ext-link ext-link-type="uri" xlink:href="http://vassarstats.net/utest.html">http://vassarstats.net/utest.html</ext-link>
</p></fn></fn-group><ref-list content-type="cited-references" id="jvim14842-bibl-0001"><title>References</title><ref id="jvim14842-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jvim14842-cit-0001">
<string-name>
<surname>Dantas&#x02010;Torres</surname>
<given-names>F</given-names>
</string-name>. <article-title>The brown dog tick, <italic>Rhipicephalus sanguineus</italic> (Latreille, 1806) (Acari: Ixodidae): From taxonomy to control</article-title>. <source>Vet Parasitol</source>
<year>2008</year>;<volume>152</volume>:<fpage>173</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">18280045</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jvim14842-cit-0002">
<string-name>
<surname>Harrus</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Waner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bark</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Recent advances in determining the pathogenesis of canine monocytic ehrlichiosis</article-title>. <source>J Clin Microbiol</source>
<year>1999</year>;<volume>37</volume>:<fpage>2745</fpage>&#x02013;<lpage>2749</lpage>.<pub-id pub-id-type="pmid">10449445</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jvim14842-cit-0003">
<string-name>
<surname>Sainz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roura</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Mir&#x000f3;</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Guideline for veterinary practitioners on canine ehrlichiosis and anaplasmosis in Europe</article-title>. <source>Parasit Vectors</source>
<year>2015</year>;<volume>8</volume>:<fpage>75</fpage>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13071-015-0649-0">https://doi.org/10.1186/s13071-015-0649-0</ext-link>.<pub-id pub-id-type="pmid">25649069</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jvim14842-cit-0004">
<string-name>
<surname>Coles</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Dryden</surname>
<given-names>MW</given-names>
</string-name>. <article-title>Insecticide/acaricide resistance in fleas and ticks infesting dogs and cats</article-title>. <source>Parasit Vectors</source>
<year>2014</year>;<volume>7</volume>:<fpage>8</fpage>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1756-3305-7-8">https://doi.org/10.1186/1756-3305-7-8</ext-link>.<pub-id pub-id-type="pmid">24393426</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jvim14842-cit-0005">
<string-name>
<surname>Neer</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Breitschwerdt</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Lappin</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Consensus statement on ehrlichial disease of small animals from the infectious disease study group of the ACVIM. American College of Veterinary Internal Medicine</article-title>. <source>J Vet Intern Med</source>
<year>2002</year>;<volume>16</volume>:<fpage>309</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">12041661</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jvim14842-cit-0006">
<string-name>
<surname>Harrus</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kenny</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Miara</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Comparison of simultaneous splenic sample PCR with blood sample PCR for diagnosis and treatment of experimental <italic>Ehrlichia canis</italic> infection</article-title>. <source>Antimicrob Agents Chemother</source>
<year>2004</year>;<volume>48</volume>:<fpage>4488</fpage>&#x02013;<lpage>4490</lpage>.<pub-id pub-id-type="pmid">15504892</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jvim14842-cit-0007">
<string-name>
<surname>Lakshmanan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gomathinayagam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dhinakarraj</surname>
<given-names>G</given-names>
</string-name>. <article-title>Molecular detection of <italic>Ehrlichia canis</italic> from blood of naturally infected dogs in India</article-title>. <source>Vet Arh</source>
<year>2007</year>;<volume>77</volume>:<fpage>307</fpage>&#x02013;<lpage>312</lpage>.</mixed-citation></ref><ref id="jvim14842-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jvim14842-cit-0008">
<string-name>
<surname>Schaefer</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Needham</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Bremer</surname>
<given-names>WG</given-names>
</string-name>, et&#x000a0;al. <article-title>Tick acquisition of <italic>Ehrlichia canis</italic> from dogs treated with doxycycline hyclate</article-title>. <source>Antimicrob Agents Chemother</source>
<year>2007</year>;<volume>51</volume>:<fpage>3394</fpage>&#x02013;<lpage>3396</lpage>.<pub-id pub-id-type="pmid">17606682</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jvim14842-cit-0009">
<string-name>
<surname>Harrus</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Waner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Aizenberg</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bark</surname>
<given-names>H</given-names>
</string-name>. <article-title>Therapeutic effect of doxycycline in experimental subclinical canine monocytic ehrlichiosis: Evaluation of a 6&#x02010;week course</article-title>. <source>J Clin Microbiol</source>
<year>1998</year>;<volume>36</volume>:<fpage>2140</fpage>&#x02013;<lpage>2142</lpage>.<pub-id pub-id-type="pmid">9650986</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="jvim14842-cit-0010">
<collab collab-type="authors">CDC</collab>
. <article-title>Nationwide shortage of doxycycline: Resources for providers and recommendations for patient care</article-title>. Center for Disease Control Health Alert Network CCDHAN&#x02010;00349, June 12, 2013. Available at: <ext-link ext-link-type="uri" xlink:href="http://emergency.cdc.gov/HAN/han00349.asp">http://emergency.cdc.gov/HAN/han00349.asp</ext-link>. Accessed 1 May 2014.</mixed-citation></ref><ref id="jvim14842-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jvim14842-cit-0011">
<string-name>
<surname>Carris</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Pardo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Montero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shaeer</surname>
<given-names>KM</given-names>
</string-name>. <article-title>Minocycline as a substitute for doxycycline in targeted scenarios: A systematic review</article-title>. <source>Open Forum Infect Dis</source>
<year>2015</year>;<volume>2</volume>:<fpage>ofv178</fpage>.<pub-id pub-id-type="pmid">26719847</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="jvim14842-cit-0012">
<string-name>
<surname>Thrill</surname>
<given-names>M</given-names>
</string-name> (ed). <article-title>The Doxycycline shortage</article-title>. Veterinary advantage: Companion 2013; 5:6. Available at <ext-link ext-link-type="uri" xlink:href="http://www.vet-advantage.com/archives/view_article.php?magazine_id=66Amp;article_id=793">http://www.vet-advantage.com/archives/view_article.php?magazine_id=66Amp;article_id=793</ext-link>. Accessed 1 May 2014.</mixed-citation></ref><ref id="jvim14842-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jvim14842-cit-0013">
<string-name>
<surname>KuKanich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>KuKanich</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Heinrich</surname>
<given-names>E</given-names>
</string-name>. <article-title>Effect of sucralfate on oral minocycline absorption in healthy dogs</article-title>. <source>J Vet Pharmacol Ther</source>
<year>2014</year>;<volume>37</volume>:<fpage>451</fpage>&#x02013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">24611544</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jvim14842-cit-0014">
<string-name>
<surname>Maaland</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Guardabassi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Papich</surname>
<given-names>MG</given-names>
</string-name>. <article-title>Minocycline pharmacokinetics and pharmacodynamics in dogs: Dosage recommendations for treatment of meticillin&#x02010;resistant Staphylococcus pseudintermedius infections</article-title>. <source>Vet Dermatol</source>
<year>2014</year>;<volume>25</volume>:<fpage>182</fpage>&#x02013;<lpage>190</lpage>.<pub-id pub-id-type="pmid">24840325</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jvim14842-cit-0015">
<string-name>
<surname>Hnot</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Lorch</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Evaluation of canine&#x02010;specific minocycline and doxycycline susceptibility breakpoints for meticillin&#x02010;resistant Staphylococcus pseudintermedius isolates from dogs</article-title>. <source>Vet Dermatol</source>
<year>2015</year>;<volume>26</volume>:<fpage>334</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">26216025</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jvim14842-cit-0016">
<string-name>
<surname>Hnot</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Lorch</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Effect of feeding on the pharmacokinetics of oral minocycline in healthy research dogs</article-title>. <source>Vet Dermatol</source>
<year>2015</year>;<volume>26</volume>:<fpage>399</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">26283447</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jvim14842-cit-0017">
<string-name>
<surname>Sorenmo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Duda</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Barber</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Canine hemangiosarcoma treated with standard chemotherapy and minocycline</article-title>. <source>J Vet Intern Med</source>
<year>2000</year>;<volume>14</volume>:<fpage>395</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">10935889</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jvim14842-cit-0018">
<string-name>
<surname>Woody</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Hoskins</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Ehrlichial diseases of dogs</article-title>. <source>Vet Clin North Am Small Anim Pract</source>
<year>1991</year>;<volume>21</volume>:<fpage>75</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">2014630</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jvim14842-cit-0019">
<string-name>
<surname>Barza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Shanks</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Relation between lipophilicity and pharmacological behaviour of minocycline, doxycycline, tetracycline and oxytetracycline in dogs</article-title>. <source>Antimicrob Agents Chemother</source>
<year>1975</year>;<volume>8</volume>:<fpage>713</fpage>&#x02013;<lpage>720</lpage>.<pub-id pub-id-type="pmid">1211925</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jvim14842-cit-0020">
<string-name>
<surname>Chopra</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>M</given-names>
</string-name>. <article-title>Tetracycline antibiotics: Mode of action, application, molecular biology and epidemiology of bacterial resistance</article-title>. <source>Microbiol Mol Biol Rev</source>
<year>2001</year>;<volume>65</volume>:<fpage>232</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">11381101</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jvim14842-cit-0021">
<string-name>
<surname>Kodama</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Senba</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamachi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>T</given-names>
</string-name>. <article-title>Clinical study of Japanese spotted fever and its aggravating factors</article-title>. <source>J Infect Chemother</source>
<year>2003</year>;<volume>9</volume>:<fpage>83</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">12673413</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jvim14842-cit-0022">
<string-name>
<surname>Hildebrandt</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Huxsoll</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>JS</given-names>
</string-name>, et&#x000a0;al. <article-title>Pathology of canine ehrlichiosis (tropical canine pancytopenia)</article-title>. <source>Am J Vet Res</source>
<year>1973</year>;<volume>34</volume>:<fpage>1309</fpage>&#x02013;<lpage>1320</lpage>.<pub-id pub-id-type="pmid">4542936</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jvim14842-cit-0023">
<string-name>
<surname>Kaewmongkol</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Maneesaay</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Suwanna</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>First detection of <italic>Ehrlichia canis</italic> in cerebrospinal fluid from a nonthrombocytopenic dog with meningoencephalitis by broad&#x02010;range PCR</article-title>. <source>J Vet Intern Med</source>
<year>2016</year>;<volume>30</volume>:<fpage>255</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">26610407</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jvim14842-cit-0024">
<string-name>
<surname>Kelly</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Ehrlichiosis, babesiosis, anaplasmosis and hepatozoonosis in dogs from St. Kitts, West Indies</article-title>. <source>PLoS One</source>
<year>2013</year>;<volume>8</volume>:<fpage>e53450</fpage>.<pub-id pub-id-type="pmid">23335965</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jvim14842-cit-0025">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>W</given-names>
</string-name>, et&#x000a0;al. <article-title>Development of generic <italic>Ehrlichia</italic> FTER&#x02010;qPCR and investigation of ehrlichiosis in domestic ruminants on five Caribbean island</article-title>. <source>Parasit Vectors</source>
<year>2015</year>;<volume>8</volume>:<fpage>506</fpage>.<pub-id pub-id-type="pmid">26438311</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jvim14842-cit-0026">
<string-name>
<surname>Caplin</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Bernard</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Wittwer</surname>
<given-names>CT</given-names>
</string-name>. <article-title>LightCycler&#x02122; hybridization probes: The most direct way to monitor PCR amplification for quantification and mutation detection</article-title>. <source>Biochemica Roche Molecular Biochemicals</source>
<year>1999</year>;<volume>1</volume>:<fpage>5</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="jvim14842-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jvim14842-cit-0027">
<string-name>
<surname>Loftis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Tick&#x02010;borne pathogens and diseases in dogs on St. Kitts, West Indies</article-title>. <source>Vet Parasitol</source>
<year>2013</year>;<volume>196</volume>:<fpage>44</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">23481028</pub-id></mixed-citation></ref><ref id="jvim14842-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="jvim14842-cit-0028">
<collab collab-type="authors">American Animal Hospital Association</collab>
. <article-title>Compliance: a report of the 2009 AAHA compliance follow&#x02010;up study</article-title>. Available at <ext-link ext-link-type="uri" xlink:href="https://secure.aahanet.org/eweb/images/student/pdf/Compliance.pdf">https://secure.aahanet.org/eweb/images/student/pdf/Compliance.pdf</ext-link>. Accessed 1 May 2014.</mixed-citation></ref><ref id="jvim14842-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jvim14842-cit-0029">
<string-name>
<surname>Eddlestone</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Diniz</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Neer</surname>
<given-names>TM</given-names>
</string-name>, et&#x000a0;al. <article-title>Doxycycline clearance of experimentally induced chronic <italic>Ehrlichia canis</italic> infection in dogs</article-title>. <source>J Vet Intern Med</source>
<year>2007</year>;<volume>21</volume>:<fpage>1237</fpage>&#x02013;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">18196732</pub-id></mixed-citation></ref></ref-list></back></article>